KRAS and non-small cell lung carcinoma: In a study of 677 patients with KRAS mutated advance stage NSCLC, those with mutations in KRAS codon 13 (n = 53) had poorer outcomes in comparison to codon 12 (n = 624), with a difference in survival of 2 months (p = 0.008), after adjusting for age, sex and smoking status [26].